ALECENSA HAS DEMONSTRATED EFFICACY

IN BOTH ALK+ RESECTED AND ADVANCED NSCLC1

ALK+ RESECTED NSCLC

 

ALECENSA delivered


superior disease-free survival
vs

platinum-based chemotherapy2

 

REDUCING
THE RISK
OF DISEASE
RECURRENCE
OR DEATH BY

76%

At the time of the primary DFS analysis, in the ITT population, median DFS was not reached for ALECENSA (95% CI: NE, NE) vs 41.3 months (95% CI: 28.5, NE) for chemotherapy2

HR=0.242

(95% CI: 0.13, 0.43)
p<0.001


ALECENSA IN THE

RESECTED SETTING

ALK+ ADVANCED NSCLC

 

ALECENSA has demonstrated 
consistent overall and intracranial 
efficacy across three Phase III trials3–5

 

6 out of 10

patients

WHO STARTED
1L ALECENSA

ARE STILL
ALIVE
AFTER 5 YEARS3

An exploratory post-hoc analysis conducted at ~5 years 
after randomisation of the last patient showed an OS rate of 62.5% (95% CI: 54.3, 70.8) in patients treated with ALECENSA versus 45.5% (95% CI: 33.6, 57.4) in patients treated with crizotinib3


ALECENSA IN THE

ADVANCED SETTING

More than 92,000 patients treated


with ALECENSA in clinical practice6

Discover

ALECENSA